Senzar Asset Management LLC Purchases Shares of 22,300 Gilead Sciences, Inc. (GILD)

Share on StockTwits

Senzar Asset Management LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 22,300 shares of the biopharmaceutical company’s stock, valued at approximately $1,580,000. Gilead Sciences makes up 4.6% of Senzar Asset Management LLC’s portfolio, making the stock its 8th largest holding.

A number of other large investors also recently added to or reduced their stakes in the stock. Archford Capital Strategies LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at $106,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $132,000. Brand Asset Management Group Inc. bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $139,000. Stelac Advisory Services LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at $141,000. Finally, Mckinley Capital Management LLC Delaware boosted its holdings in shares of Gilead Sciences by 67.7% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 860 shares in the last quarter. Institutional investors and hedge funds own 78.04% of the company’s stock.

In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $77.85, for a total value of $3,892,500.00. Following the completion of the transaction, the director now owns 3,067,762 shares of the company’s stock, valued at approximately $238,825,271.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.16% of the stock is owned by insiders.

GILD opened at $74.23 on Wednesday. The company has a quick ratio of 2.92, a current ratio of 3.00 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $98.17 billion, a PE ratio of 8.67, a P/E/G ratio of -5.77 and a beta of 1.02. Gilead Sciences, Inc. has a 1 year low of $64.27 and a 1 year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.56 by $0.35. The firm had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. Gilead Sciences’s quarterly revenue was down 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.56 EPS. sell-side analysts forecast that Gilead Sciences, Inc. will post 6.56 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 27th. Stockholders of record on Friday, September 14th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 3.07%. The ex-dividend date is Thursday, September 13th. Gilead Sciences’s dividend payout ratio is presently 26.64%.

A number of analysts have recently commented on the stock. BidaskClub cut shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 20th. ValuEngine cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, June 27th. Mizuho set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, July 31st. Robert W. Baird cut shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price on the stock. in a report on Thursday, July 26th. Finally, Piper Jaffray Companies assumed coverage on shares of Gilead Sciences in a report on Wednesday, May 30th. They set a “buy” rating and a $85.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and an average target price of $88.30.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: What is a Leveraged Buyout (LBO)?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply